1
|
Wang S, Prieux M, de Bernard S, Dubois M, Laubreton D, Djebali S, Zala M, Arpin C, Genestier L, Leverrier Y, Gandrillon O, Crauste F, Jiang W, Marvel J. Exogenous IL-2 delays memory precursors generation and is essential for enhancing memory cells effector functions. iScience 2024; 27:109411. [PMID: 38510150 PMCID: PMC10952031 DOI: 10.1016/j.isci.2024.109411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 11/27/2023] [Accepted: 02/29/2024] [Indexed: 03/22/2024] Open
Abstract
To investigate the impact of paracrine IL-2 signals on memory precursor (MP) cell differentiation, we activated CD8 T cell in vitro in the presence or absence of exogenous IL-2 (ex-IL-2). We assessed memory differentiation by transferring these cells into virus-infected mice. Both conditions generated CD8 T cells that participate in the ongoing response and gave rise to similar memory cells. Nevertheless, when transferred into a naive host, T cells activated with ex-IL-2 generated a higher frequency of memory cells displaying increased functional memory traits. Single-cell RNA-seq analysis indicated that without ex-IL-2, cells rapidly acquire an MP signature, while in its presence they adopted an effector signature. This was confirmed at the protein level and in a functional assay. Overall, ex-IL-2 delays the transition into MP cells, allowing the acquisition of effector functions that become imprinted in their progeny. These findings may help to optimize the generation of therapeutic T cells.
Collapse
Affiliation(s)
- Shaoying Wang
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
| | - Margaux Prieux
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
- Laboratoire de Biologie et de Modélisation de la Cellule, Université de Lyon, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Lyon, France
| | | | - Maxence Dubois
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
| | - Daphne Laubreton
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
| | - Sophia Djebali
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
| | - Manon Zala
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Christophe Arpin
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
- Laboratoire de Biologie et de Modélisation de la Cellule, Université de Lyon, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Lyon, France
| | - Laurent Genestier
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Yann Leverrier
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
| | - Olivier Gandrillon
- Inria, Villeurbanne, France
- Laboratoire de Biologie et de Modélisation de la Cellule, Université de Lyon, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Lyon, France
| | - Fabien Crauste
- Laboratoire MAP5 (UMR CNRS 8145), Université Paris Cité, Paris, France
| | - Wenzheng Jiang
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
| | - Jacqueline Marvel
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France
| |
Collapse
|
2
|
Roux N, Miura S, Dussenne M, Tara Y, Lee SH, de Bernard S, Reynaud M, Salis P, Barua A, Boulahtouf A, Balaguer P, Gauthier K, Lecchini D, Gibert Y, Besseau L, Laudet V. The multi-level regulation of clownfish metamorphosis by thyroid hormones. Cell Rep 2023; 42:112661. [PMID: 37347665 PMCID: PMC10467156 DOI: 10.1016/j.celrep.2023.112661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 05/27/2023] [Accepted: 06/01/2023] [Indexed: 06/24/2023] Open
Abstract
Most marine organisms have a biphasic life cycle during which pelagic larvae transform into radically different juveniles. In vertebrates, the role of thyroid hormones (THs) in triggering this transition is well known, but how the morphological and physiological changes are integrated in a coherent way with the ecological transition remains poorly explored. To gain insight into this question, we performed an integrated analysis of metamorphosis of a marine teleost, the false clownfish (Amphiprion ocellaris). We show how THs coordinate a change in color vision as well as a major metabolic shift in energy production, highlighting how it orchestrates this transformation. By manipulating the activity of liver X regulator (LXR), a major regulator of metabolism, we also identify a tight link between metabolic changes and metamorphosis progression. Strikingly, we observed that these regulations are at play in the wild, explaining how hormones coordinate energy needs with available resources during the life cycle.
Collapse
Affiliation(s)
- Natacha Roux
- Sorbonne Université, CNRS, Biologie Intégrative des Organismes Marins, Observatoire Océanologique, 66650 Banyuls-sur-Mer, France; Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna son, Okinawa 904-0495, Japan
| | - Saori Miura
- Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna son, Okinawa 904-0495, Japan
| | - Mélanie Dussenne
- Sorbonne Université, CNRS, Biologie Intégrative des Organismes Marins, Observatoire Océanologique, 66650 Banyuls-sur-Mer, France
| | - Yuki Tara
- Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna son, Okinawa 904-0495, Japan
| | - Shu-Hua Lee
- Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10, Dah-Uen Rd., Jiau Shi, I-Lan 262, Taiwan
| | | | - Mathieu Reynaud
- Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna son, Okinawa 904-0495, Japan
| | - Pauline Salis
- Sorbonne Université, CNRS, Biologie Intégrative des Organismes Marins, Observatoire Océanologique, 66650 Banyuls-sur-Mer, France
| | - Agneesh Barua
- Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna son, Okinawa 904-0495, Japan
| | - Abdelhay Boulahtouf
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, University of Montpellier, 34090 Montpellier, France
| | - Patrick Balaguer
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, University of Montpellier, 34090 Montpellier, France
| | - Karine Gauthier
- Institut de Génomique Fonctionnelle de Lyon, CNRS UMR 5242, INRAE USC 1370 École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 46 allée d'Italie, 69007 Lyon, France
| | - David Lecchini
- PSL Research University, EPHE-UPVD-CNRS-UAR 3278 CRIOBE BP 1013, 98729 Papetoai, Moorea, French Polynesia; Laboratoire d'Excellence "CORAIL," 66100 Perpignan, France
| | - Yann Gibert
- Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
| | - Laurence Besseau
- Sorbonne Université, CNRS, Biologie Intégrative des Organismes Marins, Observatoire Océanologique, 66650 Banyuls-sur-Mer, France.
| | - Vincent Laudet
- Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna son, Okinawa 904-0495, Japan; Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10, Dah-Uen Rd., Jiau Shi, I-Lan 262, Taiwan.
| |
Collapse
|
3
|
Salis P, Peyran C, Morage T, de Bernard S, Nourikyan J, Coupé S, Bunet R, Planes S. RNA-Seq comparative study reveals molecular effectors linked to the resistance of Pinna nobilis to Haplosporidium pinnae parasite. Sci Rep 2022; 12:21229. [PMID: 36482098 PMCID: PMC9731998 DOI: 10.1038/s41598-022-25555-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 11/30/2022] [Indexed: 12/13/2022] Open
Abstract
With the intensification of maritime traffic, recently emerged infectious diseases have become major drivers in the decline and extinction of species. Since 2016, mass mortality events have decimated the endemic Mediterranean Sea bivalve Pinna nobilis, affecting ca. 100% of individuals. These events have largely been driven by Haplosporidium pinnae's infection, an invasive species which was likely introduced by shipping. While monitoring wild populations of P. nobilis, we observed individuals that survived such a mass mortality event during the summer of 2018 (France). We considered these individuals resistant, as they did not show any symptoms of the disease, while the rest of the population in the area was devastated. Furthermore, the parasite was not detected when we conducted a PCR amplification of a species-specific fragment of the small subunit ribosomal DNA. In parallel, the transcriptomic analysis showed evidence of some parasite RNA indicating that the resistant individuals had been exposed to the parasite without proliferating. To understand the underlying mechanisms of resistance in these individuals, we compared their gene expression with that of susceptible individuals. We performed de novo transcriptome assembly and annotated the expressed genes. A comparison of the transcriptomes in resistant and susceptible individuals highlighted a gene expression signature of the resistant phenotype. We found significant differential expressions of genes involved in immunity and cell architecture. This data provides the first insights into how individuals escape the pathogenicity associated with infection.
Collapse
Affiliation(s)
- Pauline Salis
- PSL Research University: EPHE-UPVD-CNRS, UAR 3278 CRIOBE, 66860 Perpignan, France
| | - Claire Peyran
- PSL Research University: EPHE-UPVD-CNRS, UAR 3278 CRIOBE, 66860 Perpignan, France
| | - Titouan Morage
- PSL Research University: EPHE-UPVD-CNRS, UAR 3278 CRIOBE, 66860 Perpignan, France
| | | | | | - Stéphane Coupé
- grid.12611.350000000088437055CNRS/INSU, IRD, MIO UM 110, Mediterranean Institute of Oceanography, University of Toulon, 83130 La Garde, France
| | - Robert Bunet
- Institut Océanographique Paul Ricard, Ile des Embiez, 83140 Six-Fours-Les-Plages, France
| | - Serge Planes
- PSL Research University: EPHE-UPVD-CNRS, UAR 3278 CRIOBE, 66860 Perpignan, France ,grid.452595.aLaboratoire d’Excellence “CORAIL”, Perpignan, France
| |
Collapse
|
4
|
Todorov H, Prieux M, Laubreton D, Bouvier M, Wang S, de Bernard S, Arpin C, Cannoodt R, Saelens W, Bonnaffoux A, Gandrillon O, Crauste F, Saeys Y, Marvel J. CD8 memory precursor cell generation is a continuous process. iScience 2022; 25:104927. [PMID: 36065187 PMCID: PMC9440290 DOI: 10.1016/j.isci.2022.104927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 06/21/2022] [Accepted: 08/09/2022] [Indexed: 11/30/2022] Open
Abstract
In this work, we studied the generation of memory precursor cells following an acute infection by analyzing single-cell RNA-seq data that contained CD8 T cells collected during the postinfection expansion phase. We used different tools to reconstruct the developmental trajectory that CD8 T cells followed after activation. Cells that exhibited a memory precursor signature were identified and positioned on this trajectory. We found that these memory precursors are generated continuously with increasing numbers arising over time. Similarly, expression of genes associated with effector functions was also found to be raised in memory precursors at later time points. The ability of cells to enter quiescence and differentiate into memory cells was confirmed by BrdU pulse-chase experiment in vivo. Analysis of cell counts indicates that the vast majority of memory cells are generated at later time points from cells that have extensively divided. Trajectory inference tools reconstruct the timing of memory precursors generation The trajectory is defined by both cell cycle and effector functions encoding genes Memory precursors numbers in lymphoid organs increase with time after priming In vivo BrdU labeling validate the in silico data
Collapse
Affiliation(s)
- Helena Todorov
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
- Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium
| | - Margaux Prieux
- Centre International de recherche en Infectiologie, Université de Lyon, INSERM U1111, CNRS UMR 5308, Ecole Normale Superieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
- Laboratoire de Biologie et de Modélisation de la cellule, Université de Lyon, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Lyon, France
| | - Daphne Laubreton
- Centre International de recherche en Infectiologie, Université de Lyon, INSERM U1111, CNRS UMR 5308, Ecole Normale Superieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Matteo Bouvier
- Laboratoire de Biologie et de Modélisation de la cellule, Université de Lyon, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Lyon, France
- Vidium, Lyon, France
| | - Shaoying Wang
- Centre International de recherche en Infectiologie, Université de Lyon, INSERM U1111, CNRS UMR 5308, Ecole Normale Superieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | | | - Christophe Arpin
- Centre International de recherche en Infectiologie, Université de Lyon, INSERM U1111, CNRS UMR 5308, Ecole Normale Superieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Robrecht Cannoodt
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
- Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium
- Data Intuitive, Lebbeke, Belgium
| | - Wouter Saelens
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
- Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium
| | | | - Olivier Gandrillon
- Laboratoire de Biologie et de Modélisation de la cellule, Université de Lyon, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Lyon, France
- Inria, Villeurbanne, France
| | - Fabien Crauste
- Laboratoire MAP5 (UMR CNRS 8145), Université de Paris, Paris, France
| | - Yvan Saeys
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
- Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium
| | - Jacqueline Marvel
- Centre International de recherche en Infectiologie, Université de Lyon, INSERM U1111, CNRS UMR 5308, Ecole Normale Superieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
- Corresponding author
| |
Collapse
|
5
|
Bonduelle O, Chaudesaigues C, Tolazzi M, Suleiman E, de Bernard S, Alves K, Nourikyan J, Bohec M, Baudrin LG, Katinger D, Debré P, Scarlatti G, Vieillard V, Combadière B. Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation. Front Immunol 2022; 13:848571. [PMID: 35464449 PMCID: PMC9021396 DOI: 10.3389/fimmu.2022.848571] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Accepted: 02/22/2022] [Indexed: 01/28/2023] Open
Abstract
W614A-3S peptide is a modified 3S motif of the HIV-gp41 (mutation W614A). We previously detected the presence of natural neutralizing antibodies directed against W614A-3S peptide (NAbs) in long-term non-progressor HIV+ patients. Here, we compared the efficacy of W614A-3S peptide formulated in either squalene emulsion (SQE) or in aluminum hydroxide (Alum) in inducing broadly-NAbs (bNAbs). Rabbit and mouse models were used to screen the induction of bNAbs following 4 immunizations. SQE was more efficient than Alum formulation in inducing W614A-3S-specific bNAbs with up to 67%-93% of HIV strains neutralized. We then analyzed the quality of peptide-specific murine B cells by single-cell gene expression by quantitative reverse transcription-PCR and single-cell V(D)J sequencing. We found more frequent germinal center B cells in SQE than in Alum, albeit with a different gene expression profile. The V(D)J sequencing of W614A-3S-specific BCR showed significant differences in BCR sequences and validates the dichotomy between adjuvant formulations. All sixteen BCR sequences which were cloned were specific of peptide. Adjuvant formulations of W614A-3S-peptide-conjugated immunogen impact the quantity and quality of B cell immune responses at both the gene expression level and BCR sequence.
Collapse
Affiliation(s)
- Olivia Bonduelle
- Sorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Chloé Chaudesaigues
- Sorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Monica Tolazzi
- Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy
| | - Ehsan Suleiman
- Polymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria
| | | | | | | | - Mylene Bohec
- Institut Curie, Genomics of Excellence (ICGex) Platform, Paris Science et Lettres (PSL) Research University, Paris, France
| | - Laura G Baudrin
- Institut Curie, Genomics of Excellence (ICGex) Platform, Paris Science et Lettres (PSL) Research University, Paris, France
| | - Dietmar Katinger
- Polymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria
| | - Patrice Debré
- Sorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Gabriella Scarlatti
- Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy
| | - Vincent Vieillard
- Sorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Behazine Combadière
- Sorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| |
Collapse
|
6
|
Bauer Y, de Bernard S, Hickey P, Ballard K, Cruz J, Cornelisse P, Chadha-Boreham H, Distler O, Rosenberg D, Doelberg M, Roux S, Nayler O, Lawrie A. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. Eur Respir J 2021; 57:13993003.02591-2020. [PMID: 33334933 PMCID: PMC8276065 DOI: 10.1183/13993003.02591-2020] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 11/17/2020] [Indexed: 12/31/2022]
Abstract
Pulmonary arterial hypertension (PAH) is a devastating complication of systemic sclerosis (SSc). Screening for PAH in SSc has increased detection, allowed early treatment for PAH and improved patient outcomes. Blood-based biomarkers that reliably identify SSc patients at risk of PAH, or with early disease, would significantly improve screening, potentially leading to improved survival, and provide novel mechanistic insights into early disease. The main objective of this study was to identify a proteomic biomarker signature that could discriminate SSc patients with and without PAH using a machine learning approach and to validate the findings in an external cohort. Serum samples from patients with SSc and PAH (n=77) and SSc without pulmonary hypertension (non-PH) (n=80) were randomly selected from the clinical DETECT study and underwent proteomic screening using the Myriad RBM Discovery platform consisting of 313 proteins. Samples from an independent validation SSc cohort (PAH n=22 and non-PH n=22) were obtained from the University of Sheffield (Sheffield, UK). Random forest analysis identified a novel panel of eight proteins, comprising collagen IV, endostatin, insulin-like growth factor binding protein (IGFBP)-2, IGFBP-7, matrix metallopeptidase-2, neuropilin-1, N-terminal pro-brain natriuretic peptide and RAGE (receptor for advanced glycation end products), that discriminated PAH from non-PH in SSc patients in the DETECT Discovery Cohort (average area under the receiver operating characteristic curve 0.741, 65.1% sensitivity/69.0% specificity), which was reproduced in the Sheffield Confirmatory Cohort (81.1% accuracy, 77.3% sensitivity/86.5% specificity). This novel eight-protein biomarker panel has the potential to improve early detection of PAH in SSc patients and may provide novel insights into the pathogenesis of PAH in the context of SSc. Early screening for pulmonary arterial hypertension in patients with systemic sclerosis improves patient outcome. This study identified a novel eight-protein biomarker panel that has the potential to assist early detection of PAH in this patient group.https://bit.ly/373BNkL
Collapse
Affiliation(s)
- Yasmina Bauer
- Galapagos GmbH, Basel, Switzerland.,Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| | | | - Peter Hickey
- Dept of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.,Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
| | | | | | | | | | - Oliver Distler
- Dept of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | | | | | | | | | - Allan Lawrie
- Dept of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK
| |
Collapse
|
7
|
Mahe YF, Cheniti A, Tacheau C, Antonelli R, Planard-Luong L, de Bernard S, Buffat L, Barbarat P, Kanoun-Copy L. Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. Lasers Surg Med 2021; 53:1208-1219. [PMID: 33973663 PMCID: PMC9292036 DOI: 10.1002/lsm.23398] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 02/04/2021] [Accepted: 02/27/2021] [Indexed: 01/25/2023]
Abstract
BACKGROUND AND OBJECTIVES Low-level light therapies using visible to infrared light are known to activate several cellular functions, such as adenosine triphosphate and nitric oxide synthesis. However, few clinical observations report its biological consequences for skin and scalp homeostasis. Since scalp inflammation was recognized as a potential physiological obstacle to the efficacy of the reference hair regrowth drug Minoxidil in vivo and since perifollicular inflammation is the hallmark of about 50%-70% follicular units in androgenetic alopecia, we decided to investigate whether the anti-inflammatory activity of LLLT/GentleWaves® device were assigned to L'Oréal by Light BioScience L.L.C., Virginia Beach, VA (US) could enhance hair regrowth activity of Minoxidil. STUDY DESIGN/MATERIALS AND METHODS We conducted a first experimental clinical study on 64 men with androgenetic alopecia using LLLT/GentleWaves®, 590-nm predominant wavelength 70 seconds, specifically pulsed once per day, for 3 days, and we performed a whole-genome analysis of treated scalp biopsies. In a second clinical study, including 135 alopecic volunteers, we evaluated the hair regrowth activity in response to the upgraded LLLT/GentleWaves® device and Minoxidil. RESULTS In the first clinical study, whole-genome analysis of treated scalp biopsies showed downregulation of scalp inflammatory biomarkers, such as AP1/FOSB messenger RNA (mRNA) and mir21, together with the disappearance of CD69 mRNA, specific to scalp-infiltrating T cells of about 50% of the studied volunteers prior to the LLLT/GentleWaves® treatment. In the second clinical study, we observed that LLLT/GentleWaves® was able to boost the hair regrowth activity of a Minoxidil 2% lotion to the extent of the highest concentration (5%) in terms of efficacy, number of responders, and perceived performance. CONCLUSIONS Altogether, these observations suggest the potential benefit of LLLT/GentleWaves® as a noninvasive adjunctive technology for skin and scalp conditions, where a mild perifollicular inflammation is involved. Lasers Surg. Med. 2021. Copyright © 2021 Wiley Periodicals LLC.
Collapse
Affiliation(s)
- Yann F Mahe
- L'OREAL Research and Innovation, 1, avenue Eugène Schueller, Aulnay-sous-Bois, 93600, France
| | - Ahsène Cheniti
- L'OREAL Research and Innovation, 1, avenue Eugène Schueller, Aulnay-sous-Bois, 93600, France
| | - Charlotte Tacheau
- L'OREAL Research and Innovation, 1, avenue Eugène Schueller, Aulnay-sous-Bois, 93600, France
| | - Rosaria Antonelli
- L'OREAL Research and Innovation, 188, rue Paul Hochart, Chevilly Larue, 94550, France
| | - Lien Planard-Luong
- L'OREAL Research and Innovation, 188, rue Paul Hochart, Chevilly Larue, 94550, France
| | | | - Laurent Buffat
- ALTRABIO, Bât. l'Initial 30 rue Pré-Gaudry, Lyon, 69007, France
| | - Philippe Barbarat
- L'OREAL Research and Innovation, 1, avenue Eugène Schueller, Aulnay-sous-Bois, 93600, France
| | - Leila Kanoun-Copy
- L'OREAL Research and Innovation, 188, rue Paul Hochart, Chevilly Larue, 94550, France
| |
Collapse
|
8
|
Sanchez J, Gonçalves E, Llano A, Gonzáles P, Fernández-Maldonado M, Vogt A, Soria A, Perez S, Cedeño S, Fernández MA, Nourikyan J, de Bernard S, Ganoza C, Pedruzzi E, Bonduelle O, Mothe B, Gòmez CE, Esteban M, Garcia F, Lama JR, Brander C, Combadiere B. Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study. Front Immunol 2020; 11:586124. [PMID: 33244316 PMCID: PMC7683801 DOI: 10.3389/fimmu.2020.586124] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 10/12/2020] [Indexed: 12/04/2022] Open
Abstract
Background Our previous work has demonstrated the benefits of transcutaneous immunization in targeting Langerhans cells and preferentially inducing CD8 T-cell responses. Methods In this randomized phase Ib clinical trial including 20 HIV uninfected volunteers, we compared the safety and immunogenicity of the MVA recombinant vaccine expressing HIV-B antigen (MVA-B) by transcutaneous and intramuscular routes. We hypothesized that the quality of innate and adaptive immunity differs according to the route of immunization and explored the quality of the vector vaccine-induced immune responses. We also investigated the early blood transcriptome and serum cytokine levels to identify innate events correlated with the strength and quality of adaptive immunity. Results We demonstrate that MVA-B vaccine is safe by both routes, but that the quality and intensity of both innate and adaptive immunity differ significantly. Transcutaneous vaccination promoted CD8 responses in the absence of antibodies and slightly affected gene expression, involving mainly genes associated with metabolic pathways. Intramuscular vaccination, on the other hand, drove robust changes in the expression of genes involved in IL-6 and interferon signalling pathways, mainly those associated with humoral responses, and also some levels of CD8 response. Conclusion Thus, vaccine delivery route perturbs early innate responses that shape the quality of adaptive immunity. Clinical Trial Registration http://ClinicalTrials.gov, identifier PER-073-13.
Collapse
Affiliation(s)
- Jorge Sanchez
- Centro de Investigaciones Tecnológicas, Biomedicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru
| | - Elena Gonçalves
- Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France
| | - Anuska Llano
- IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | | | | | - Annika Vogt
- Clinical Research Center for Hair and Skin Science, Department of Dermatology, Venerology and Allergy, Charité-Universitatsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | | | - Susana Perez
- Centro de Investigaciones Tecnológicas, Biomedicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru
| | - Samandhy Cedeño
- IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | - Marco Antonio Fernández
- Flow Cytometry Facility, Germans Trias i Pujol Research Institute (IGTP), Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | | | | | | | - Eric Pedruzzi
- Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France
| | - Olivia Bonduelle
- Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France
| | - Beatriz Mothe
- IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.,Fundació Lluita contra la Sida, Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Carmen E Gòmez
- Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Mariano Esteban
- Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Felipe Garcia
- Infectious Diseases Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Javier R Lama
- Asociacion Civil Impacta Salud y Educacion, Lima, Peru
| | - Christian Brander
- IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.,Faculty of Medicine, Universitat de Vic-Central de Catalunya (UVic-UCC), Vic, Spain.,Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain
| | - Behazine Combadiere
- Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France
| |
Collapse
|
9
|
Grau M, Valsesia S, Mafille J, Djebali S, Tomkowiak M, Mathieu AL, Laubreton D, de Bernard S, Jouve PE, Ventre E, Buffat L, Walzer T, Leverrier Y, Marvel J. Antigen-Induced but Not Innate Memory CD8 T Cells Express NKG2D and Are Recruited to the Lung Parenchyma upon Viral Infection. J Immunol 2018; 200:3635-3646. [PMID: 29632146 DOI: 10.4049/jimmunol.1701698] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 03/12/2018] [Indexed: 12/22/2022]
Abstract
The pool of memory-phenotype CD8 T cells is composed of Ag-induced (AI) and cytokine-induced innate (IN) cells. IN cells have been described as having properties similar to those of AI memory cells. However, we found that pathogen-induced AI memory cells can be distinguished in mice from naturally generated IN memory cells by surface expression of NKG2D. Using this marker, we described the increased functionalities of AI and IN memory CD8 T cells compared with naive cells, as shown by comprehensive analysis of cytokine secretion and gene expression. However, AI differed from IN memory CD8 T cells by their capacity to migrate to the lung parenchyma upon inflammation or infection, a process dependent on their expression of ITGA1/CD49a and ITGA4/CD49d integrins.
Collapse
Affiliation(s)
- Morgan Grau
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Séverine Valsesia
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Julien Mafille
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Sophia Djebali
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Martine Tomkowiak
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Anne-Laure Mathieu
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Daphné Laubreton
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | | | | | - Erwan Ventre
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | | | - Thierry Walzer
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Yann Leverrier
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| | - Jacqueline Marvel
- Centre International de Recherche en Infectiologie, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, F-69007 Lyon, France; and
| |
Collapse
|
10
|
Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A, Roux S, Nayler O. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2017; 3:00074-2016. [PMID: 28435843 PMCID: PMC5395293 DOI: 10.1183/23120541.00074-2016] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Accepted: 12/31/2016] [Indexed: 01/10/2023] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis, which is characterised by destruction of normal lung architecture and excessive deposition of lung extracellular matrix. The heterogeneity of disease progression in patients with IPF poses significant obstacles to patient care and prevents efficient development of novel therapeutic interventions. Blood biomarkers, reflecting pathobiological processes in the lung, could provide objective evidence of the underlying disease. Longitudinally collected serum samples from the Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial were used to measure four biomarkers (metalloproteinase-7 (MMP-7), Fas death receptor ligand, osteopontin and procollagen type I C-peptide), to assess their potential prognostic capabilities and to follow changes during disease progression in patients with IPF. In baseline BUILD-3 samples, only MMP-7 showed clearly elevated protein levels compared with samples from healthy controls, and further investigations demonstrated that MMP-7 levels also increased over time. Baseline levels of MMP-7 were able to predict patients who had higher risk of worsening and, notably, baseline levels of MMP-7 could predict changes in FVC as early as month 4. MMP-7 shows potential to be a reliable predictor of lung function decline and disease progression.
Collapse
Affiliation(s)
- Yasmina Bauer
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | | | | | | | | | | | - Sebastien Roux
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.,These authors contributed equally to this research
| | - Oliver Nayler
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.,These authors contributed equally to this research
| |
Collapse
|
11
|
Blanc P, Moro-Sibilot L, Barthly L, Jagot F, This S, de Bernard S, Buffat L, Dussurgey S, Colisson R, Hobeika E, Fest T, Taillardet M, Thaunat O, Sicard A, Mondière P, Genestier L, Nutt SL, Defrance T. Mature IgM-expressing plasma cells sense antigen and develop competence for cytokine production upon antigenic challenge. Nat Commun 2016; 7:13600. [PMID: 27924814 PMCID: PMC5150646 DOI: 10.1038/ncomms13600] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Accepted: 10/17/2016] [Indexed: 12/02/2022] Open
Abstract
Dogma holds that plasma cells, as opposed to B cells, cannot bind antigen because they have switched from expression of membrane-bound immunoglobulins (Ig) that constitute the B-cell receptor (BCR) to production of the secreted form of immunoglobulins. Here we compare the phenotypical and functional attributes of plasma cells generated by the T-cell-dependent and T-cell-independent forms of the hapten NP. We show that the nature of the secreted Ig isotype, rather than the chemical structure of the immunizing antigen, defines two functionally distinct populations of plasma cells. Fully mature IgM-expressing plasma cells resident in the bone marrow retain expression of a functional BCR, whereas their IgG+ counterparts do not. Antigen boost modifies the gene expression profile of IgM+ plasma cells and initiates a cytokine production program, characterized by upregulation of CCL5 and IL-10. Our results demonstrate that IgM-expressing plasma cells can sense antigen and acquire competence for cytokine production upon antigenic challenge.
Plasma cells produce secreted antibodies and are thought to lack expression of the membrane-bound immunoglobulins that constitute B-cell receptors. Here the authors show that IgM-expressing plasma cells maintain B-cell receptor expression and initiate cytokine production following antigen stimulation.
Collapse
Affiliation(s)
- Pascal Blanc
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Ludovic Moro-Sibilot
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Lucas Barthly
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Ferdinand Jagot
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Sébastien This
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | | | | | - Sébastien Dussurgey
- INSERM SFR Biosciences Gerland, UMS3444/US8, 50 Avenue Tony Garnier, 69007 Lyon, France
| | - Renaud Colisson
- eBioscience, An Affymetrix Company, 140 bis Rue de Rennes, 75006 Paris, France
| | - Elias Hobeika
- Institute of Immunology, University Hospital, Albert Einstein Allee 11, Ulm 89073, Germany
| | - Thierry Fest
- INSERM, UMR917, F-35043 Rennes, France.,Pôle de Biologie, Centre Hospitalier Universitaire, 35033 Rennes, France.,Université de Rennes 1, F-35065 Rennes, France
| | - Morgan Taillardet
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Olivier Thaunat
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Antoine Sicard
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Paul Mondière
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Laurent Genestier
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Stephen L Nutt
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Thierry Defrance
- CIRI, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ. Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| |
Collapse
|
12
|
Brinza L, Djebali S, Tomkowiak M, Mafille J, Loiseau C, Jouve PE, de Bernard S, Buffat L, Lina B, Ottmann M, Rosa-Calatrava M, Schicklin S, Bonnefoy N, Lauvau G, Grau M, Wencker M, Arpin C, Walzer T, Leverrier Y, Marvel J. Immune signatures of protective spleen memory CD8 T cells. Sci Rep 2016; 6:37651. [PMID: 27883012 PMCID: PMC5121635 DOI: 10.1038/srep37651] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 10/28/2016] [Indexed: 01/09/2023] Open
Abstract
Memory CD8 T lymphocyte populations are remarkably heterogeneous and differ in their ability to protect the host. In order to identify the whole range of qualities uniquely associated with protective memory cells we compared the gene expression signatures of two qualities of memory CD8 T cells sharing the same antigenic-specificity: protective (Influenza-induced, Flu-TM) and non-protective (peptide-induced, TIM) spleen memory CD8 T cells. Although Flu-TM and TIM express classical phenotypic memory markers and are polyfunctional, only Flu-TM protects against a lethal viral challenge. Protective memory CD8 T cells express a unique set of genes involved in migration and survival that correlate with their unique capacity to rapidly migrate within the infected lung parenchyma in response to influenza infection. We also enlighten a new set of poised genes expressed by protective cells that is strongly enriched in cytokines and chemokines such as Ccl1, Ccl9 and Gm-csf. CCL1 and GM-CSF genes are also poised in human memory CD8 T cells. These immune signatures are also induced by two other pathogens (vaccinia virus and Listeria monocytogenes). The immune signatures associated with immune protection were identified on circulating cells, i.e. those that are easily accessible for immuno-monitoring and could help predict vaccines efficacy.
Collapse
Affiliation(s)
- Lilia Brinza
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Sophia Djebali
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Martine Tomkowiak
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Julien Mafille
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Céline Loiseau
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | | | | | | | - Bruno Lina
- Laboratoire Virpath EA4610, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Université de Lyon, France.,Laboratoire de Virologie, CNR des virus influenza, Hospices Civils de Lyon, Lyon, France
| | - Michèle Ottmann
- Laboratoire Virpath EA4610, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Université de Lyon, France
| | - Manuel Rosa-Calatrava
- Laboratoire Virpath EA4610, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Université de Lyon, France
| | - Stéphane Schicklin
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Nathalie Bonnefoy
- IRCM, Institut de Recherche en Cancérologie de Montpellier; INSERM, U896; Université Montpellier 1; CRLC Val d'Aurelle Paul Lamarque, Montpellier, France
| | - Grégoire Lauvau
- Albert Einstein College of Medicine, Department of Microbiology and Immunology, Bronx, NY 10461, USA
| | - Morgan Grau
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Mélanie Wencker
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Christophe Arpin
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Thierry Walzer
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Yann Leverrier
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| | - Jacqueline Marvel
- CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
| |
Collapse
|
13
|
Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatzu G, Mondière P, Schrader A, Taillardet M, Thaunat O, Martin N, Dalle S, Le Garff-Tavernier M, Salles G, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, Genestier L. CD1d-restricted peripheral T cell lymphoma in mice and humans. J Exp Med 2016; 213:841-57. [PMID: 27069116 PMCID: PMC4854725 DOI: 10.1084/jem.20150794] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 02/25/2016] [Indexed: 12/18/2022] Open
Abstract
Peripheral T cell lymphomas (PTCLs) are a heterogeneous entity of neoplasms with poor prognosis, lack of effective therapies, and a largely unknown pathophysiology. Identifying the mechanism of lymphomagenesis and cell-of-origin from which PTCLs arise is crucial for the development of efficient treatment strategies. In addition to the well-described thymic lymphomas, we found that p53-deficient mice also developed mature PTCLs that did not originate from conventional T cells but from CD1d-restricted NKT cells. PTCLs showed phenotypic features of activated NKT cells, such as PD-1 up-regulation and loss of NK1.1 expression. Injections of heat-killed Streptococcus pneumonia, known to express glycolipid antigens activating NKT cells, increased the incidence of these PTCLs, whereas Escherichia coli injection did not. Gene expression profile analyses indicated a significant down-regulation of genes in the TCR signaling pathway in PTCL, a common feature of chronically activated T cells. Targeting TCR signaling pathway in lymphoma cells, either with cyclosporine A or anti-CD1d blocking antibody, prolonged mice survival. Importantly, we identified human CD1d-restricted lymphoma cells within Vδ1 TCR-expressing PTCL. These results define a new subtype of PTCL and pave the way for the development of blocking anti-CD1d antibody for therapeutic purposes in humans.
Collapse
Affiliation(s)
- Emmanuel Bachy
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France Department of Hematology, Hospices Civils de Lyon, 69004 Lyon, France Université de Lyon, Université Claude Bernard Lyon1, 69007 Lyon, France
| | - Mirjam Urb
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | - Shilpi Chandra
- Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037
| | - Rémy Robinot
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | - Gabriel Bricard
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | | | - Alexandra Traverse-Glehen
- Department of Pathology, Hospices Civils de Lyon, 69004 Lyon, France CNRS, UMR 5239, 69342 Lyon, France
| | - Sophie Gazzo
- Department of Cytogenetics, Hospices Civils de Lyon, 69004 Lyon, France CNRS, UMR 5239, 69342 Lyon, France
| | - Olivier Blond
- Institut Albert Bonniot, INSERM U823, Université J. Fourier, 38041 Grenoble, France
| | - Archana Khurana
- Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037
| | - Lucile Baseggio
- Department of Cytology, Hospices Civils de Lyon, 69004 Lyon, France CNRS, UMR 5239, 69342 Lyon, France
| | - Tayla Heavican
- Department of Pathology and Microbiology, Center for Lymphoma and Leukemia Research, University of Nebraska Medical Center, Omaha, NE 68198
| | - Martine Ffrench
- Department of Cytology, Hospices Civils de Lyon, 69004 Lyon, France CNRS, UMR 5239, 69342 Lyon, France
| | - Giuliano Crispatzu
- Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, University of Cologne, 50923 Cologne, Germany
| | - Paul Mondière
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | - Alexandra Schrader
- Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, University of Cologne, 50923 Cologne, Germany
| | - Morgan Taillardet
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | - Olivier Thaunat
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | - Nadine Martin
- INSERM U955, Créteil 94000, France Université Paris-Est, Créteil 94000, France Department of Pathology, AP-HP, Groupe Henri-Mondor Albert-Chenevier, 94000 Créteil, France
| | - Stéphane Dalle
- Department of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 69004 Lyon, France University Claude Bernard Lyon 1, 69100 Lyon, France INSERM UMR-S1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, 69003 Lyon, France
| | - Magali Le Garff-Tavernier
- Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Universités, UPMC, Université Paris 06 et Assistance Publique-Hôpitaux de Paris, 75004 Paris, France INSERM U1138, Programmed cell death and physiopathology of tumor cells, Centre de Recherche des Cordeliers, 75006 Paris, France
| | - Gilles Salles
- Department of Hematology, Hospices Civils de Lyon, 69004 Lyon, France Université de Lyon, Université Claude Bernard Lyon1, 69007 Lyon, France CNRS, UMR 5239, 69342 Lyon, France
| | - Joel Lachuer
- Université de Lyon, Université Claude Bernard Lyon1, 69007 Lyon, France INSERM UMR-S1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, 69003 Lyon, France ProfileXpert, SFR Santé Lyon-Est, UCBL UMS 3453 CNRS-US7 INSERM, 69372 Lyon, France
| | - Olivier Hermine
- Institut Imagine, Laboratoire INSERM, Unité Mixte de Recherche 1163, CNRS Équipe de Recherche Laboratoryéllisée 8254, Cellular and Molecular Basis of Hematological Disorders and Therapeutic Implications, 75015 Paris, France Service d'Hématologie, Faculté de Médecine Paris Descartes, Sorbonne Paris-Cité et Assistance Publique-Hôpitaux de Paris Hôpital Necker, 75015 Paris, France
| | - Vahid Asnafi
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades, INSERM U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75015 Paris, France
| | - Mikael Roussel
- Rennes University Hospital, Rennes INSERM UMR 917 Faculté de Médecine Université Rennes 1, 35000 Rennes, France
| | - Thierry Lamy
- Rennes University Hospital, Rennes INSERM UMR 917 Faculté de Médecine Université Rennes 1, 35000 Rennes, France
| | - Marco Herling
- Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, University of Cologne, 50923 Cologne, Germany
| | - Javeed Iqbal
- Department of Pathology and Microbiology, Center for Lymphoma and Leukemia Research, University of Nebraska Medical Center, Omaha, NE 68198
| | | | - Patrice N Marche
- Institut Albert Bonniot, INSERM U823, Université J. Fourier, 38041 Grenoble, France
| | - Philippe Gaulard
- INSERM U955, Créteil 94000, France Université Paris-Est, Créteil 94000, France Department of Pathology, AP-HP, Groupe Henri-Mondor Albert-Chenevier, 94000 Créteil, France
| | - Mitchell Kronenberg
- Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037
| | - Thierry Defrance
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| | - Laurent Genestier
- CIRI, International Center for Infectiology Research, Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale (INSERM), U1111, 69007 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Université Lyon 1, Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique (CNRS), UMR 5308, 69365 Lyon, France
| |
Collapse
|
14
|
van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marçais A, Vandamme N, Farla N, Mayol K, Viel S, Degouve S, Debien E, Seuntjens E, Conidi A, Chaix J, Mangeot P, de Bernard S, Buffat L, Haigh J, Huylebroeck D, Lambrecht BN, Berx G, Walzer T. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J Biophys Biochem Cytol 2015. [DOI: 10.1083/jcb.2113oia260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
15
|
van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marçais A, Vandamme N, Farla N, Mayol K, Viel S, Degouve S, Debien E, Seuntjens E, Conidi A, Chaix J, Mangeot P, de Bernard S, Buffat L, Haigh JJ, Huylebroeck D, Lambrecht BN, Berx G, Walzer T. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J Exp Med 2015; 212:2015-25. [PMID: 26503444 PMCID: PMC4647267 DOI: 10.1084/jem.20150809] [Citation(s) in RCA: 123] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Accepted: 09/16/2015] [Indexed: 12/03/2022] Open
Abstract
The transcription factor Zeb2 cooperates with T-bet to control NK cell maturation, viability, and exit from the bone marrow and is essential for rejection of melanoma lung metastasis. Natural killer (NK) cell maturation is a tightly controlled process that endows NK cells with functional competence and the capacity to recognize target cells. Here, we found that the transcription factor (TF) Zeb2 was the most highly induced TF during NK cell maturation. Zeb2 is known to control epithelial to mesenchymal transition, but its role in immune cells is mostly undefined. Targeted deletion of Zeb2 resulted in impaired NK cell maturation, survival, and exit from the bone marrow. NK cell function was preserved, but mice lacking Zeb2 in NK cells were more susceptible to B16 melanoma lung metastases. Reciprocally, ectopic expression of Zeb2 resulted in a higher frequency of mature NK cells in all organs. Moreover, the immature phenotype of Zeb2−/− NK cells closely resembled that of Tbx21−/− NK cells. This was caused by both a dependence of Zeb2 expression on T-bet and a probable cooperation of these factors in gene regulation. Transgenic expression of Zeb2 in Tbx21−/− NK cells partially restored a normal maturation, establishing that timely induction of Zeb2 by T-bet is an essential event during NK cell differentiation. Finally, this novel transcriptional cascade could also operate in human as T-bet and Zeb2 are similarly regulated in mouse and human NK cells.
Collapse
Affiliation(s)
- Mary J van Helden
- Laboratory of Immunoregulation and Mucosal Immunology, VIB Inflammation Research Center, 9052 Ghent, Belgium GROUP-ID Consortium, Ghent University, 9000 Ghent, Belgium Department of Respiratory Medicine, Ghent University, 9052 Ghent, Belgium
| | - Steven Goossens
- Unit of Molecular and Cellular Oncology, VIB Inflammation Research Center, 9052 Ghent, Belgium Department for Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium
| | - Cécile Daussy
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | - Anne-Laure Mathieu
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | - Fabrice Faure
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | - Antoine Marçais
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | - Niels Vandamme
- Unit of Molecular and Cellular Oncology, VIB Inflammation Research Center, 9052 Ghent, Belgium Department for Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium
| | - Natalie Farla
- Unit of Molecular and Cellular Oncology, VIB Inflammation Research Center, 9052 Ghent, Belgium Department for Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium
| | - Katia Mayol
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | - Sébastien Viel
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France Laboratoire d'Immunologie, Hospices Civils de Lyon, 69495 Lyon, France
| | - Sophie Degouve
- Department for Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France
| | - Emilie Debien
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | - Eve Seuntjens
- Laboratory of Molecular Biology (Celgen), Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
| | - Andrea Conidi
- Department of Cell Biology, Erasmus MC, 3015 CN Rotterdam, Netherlands
| | - Julie Chaix
- Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France
| | - Philippe Mangeot
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| | | | | | - Jody J Haigh
- Department for Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
| | - Danny Huylebroeck
- Laboratory of Molecular Biology (Celgen), Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium Department of Cell Biology, Erasmus MC, 3015 CN Rotterdam, Netherlands
| | - Bart N Lambrecht
- Laboratory of Immunoregulation and Mucosal Immunology, VIB Inflammation Research Center, 9052 Ghent, Belgium GROUP-ID Consortium, Ghent University, 9000 Ghent, Belgium Department of Pulmonary Medicine, Erasmus MC, 3015 CN Rotterdam, Netherlands
| | - Geert Berx
- Unit of Molecular and Cellular Oncology, VIB Inflammation Research Center, 9052 Ghent, Belgium Department for Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium
| | - Thierry Walzer
- Université de Lyon, 69007 Lyon, France Institut National de la Santé et de la Recherche Médicale, U1111, 69342 Lyon, France Ecole Normale Supérieure de Lyon, 69007 Lyon, France Centre International de Recherche en Infectiologie, 69007 Lyon, France Centre National de la Recherche Scientifique, UMR5308, 69342 Lyon, France
| |
Collapse
|
16
|
Bauer Y, Tedrow J, de Bernard S, Birker-Robaczewska M, Gibson KF, Guardela BJ, Hess P, Klenk A, Lindell KO, Poirey S, Renault B, Rey M, Weber E, Nayler O, Kaminski N. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2015; 52:217-31. [PMID: 25029475 DOI: 10.1165/rcmb.2013-0310oc] [Citation(s) in RCA: 127] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The bleomycin-induced rodent lung fibrosis model is commonly used to study mechanisms of lung fibrosis and to test potential therapeutic interventions, despite the well recognized dissimilarities to human idiopathic pulmonary fibrosis (IPF). Therefore, in this study, we sought to identify genomic commonalities between the gene expression profiles from 100 IPF lungs and 108 control lungs that were obtained from the Lung Tissue Research Consortium, and rat lungs harvested at Days 3, 7, 14, 21, 28, 42, and 56 after bleomycin instillation. Surprisingly, the highest gene expression similarity between bleomycin-treated rat and IPF lungs was observed at Day 7. At this point of maximal rat-human commonality, we identified a novel set of 12 disease-relevant translational gene markers (C6, CTHRC1, CTSE, FHL2, GAL, GREM1, LCN2, MMP7, NELL1, PCSK1, PLA2G2A, and SLC2A5) that was able to separate almost all patients with IPF from control subjects in our cohort and in two additional IPF/control cohorts (GSE10667 and GSE24206). Furthermore, in combination with diffusing capacity of carbon monoxide measurements, four members of the translational gene marker set contributed to stratify patients with IPF according to disease severity. Significantly, pirfenidone attenuated the expression change of one (CTHRC1) translational gene marker in the bleomycin-induced lung fibrosis model, in transforming growth factor-β1-treated primary human lung fibroblasts and transforming growth factor-β1-treated human epithelial A549 cells. Our results suggest that a strategy focused on rodent model-human disease commonalities may identify genes that could be used to predict the pharmacological impact of therapeutic interventions, and thus facilitate the development of novel treatments for this devastating lung disease.
Collapse
Affiliation(s)
- Yasmina Bauer
- 1 Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Idbaih A, Mokhtari K, Emile JF, Galanaud D, Belaid H, de Bernard S, Benameur N, Barlog VC, Psimaras D, Donadieu J, Carpentier C, Martin-Duverneuil N, Haroche J, Feuvret L, Zahr N, Delattre JY, Hoang-Xuan K. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 2014; 83:1478-80. [PMID: 25209580 DOI: 10.1212/wnl.0000000000000880] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Ahmed Idbaih
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France.
| | - Karima Mokhtari
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Jean-François Emile
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Damien Galanaud
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Hayat Belaid
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Simon de Bernard
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Neila Benameur
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Vlad-Ciprian Barlog
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Dimitri Psimaras
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Jean Donadieu
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Catherine Carpentier
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Nadine Martin-Duverneuil
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Julien Haroche
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Loic Feuvret
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Noel Zahr
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Jean-Yves Delattre
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| | - Khê Hoang-Xuan
- From the Université Pierre et Marie Curie-Paris 6 (A.I., K.M., C.C., J.-Y.D., K.H.-X.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975 (A.I., K.M., C.C., J.-Y.D., K.H.-X.); CNRS (A.I., K.M., C.C., J.-Y.D., K.H.-X.), UMR 7225; AP-HP (A.I., K.M., D.G., H.B., N.B., V.-C.B., D.P., N.M.-D., J.H., L.F., N.Z., J.-Y.D., K.H.-X.), Groupe Hospitalier Pitié-Salpêtrière, Paris; Versailles University & Ambroise Paré Hospital (J.-F.E.), AP-HP, Boulogne; AltraBio (S.d.B.), Lyon; and AP-HP (J.D.), Hôpital Trousseau, Paris, France
| |
Collapse
|
18
|
Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, Bienvenu J, Henry T, Debien E, Hasan UA, Marvel J, Yoh K, Takahashi S, Prinz I, de Bernard S, Buffat L, Walzer T. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. ACTA ACUST UNITED AC 2014; 211:563-77. [PMID: 24516120 PMCID: PMC3949572 DOI: 10.1084/jem.20131560] [Citation(s) in RCA: 413] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Trail(+)DX5(-)Eomes(-) natural killer (NK) cells arise in the mouse fetal liver and persist in the adult liver. Their relationships with Trail(-)DX5(+) NK cells remain controversial. We generated a novel Eomes-GFP reporter murine model to address this question. We found that Eomes(-) NK cells are not precursors of classical Eomes(+) NK cells but rather constitute a distinct lineage of innate lymphoid cells. Eomes(-) NK cells are strictly dependent on both T-bet and IL-15, similarly to NKT cells. We observed that, in the liver, expression of T-bet in progenitors represses Eomes expression and the development of Eomes(+) NK cells. Reciprocally, the bone marrow (BM) microenvironment restricts T-bet expression in developing NK cells. Ectopic expression of T-bet forces the development of Eomes(-) NK cells, demonstrating that repression of T-bet is essential for the development of Eomes(+) NK cells. Gene profile analyses show that Eomes(-) NK cells share part of their transcriptional program with NKT cells, including genes involved in liver homing and NK cell receptors. Moreover, Eomes(-) NK cells produce a broad range of cytokines, including IL-2 and TNF in vitro and in vivo, during immune responses against vaccinia virus. Thus, mutually exclusive expression of T-bet and Eomes drives the development of different NK cell lineages with complementary functions.
Collapse
Affiliation(s)
- Cécile Daussy
- CIRI, International Center for Infectiology Research, Université de Lyon; 2 Institut National de la Santé et de la Recherche Médicale, U1111; 3 Ecole Normale Supérieure de Lyon; 4 Université Lyon 1, Centre International de Recherche en Infectiologie; and 5 Centre National de la Recherche Scientifique, UMR5308, 69007 Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Samarut E, Gaudin C, Hughes S, Gillet B, de Bernard S, Jouve PE, Buffat L, Allot A, Lecompte O, Berekelya L, Rochette-Egly C, Laudet V. Retinoic acid receptor subtype-specific transcriptotypes in the early zebrafish embryo. Mol Endocrinol 2014; 28:260-72. [PMID: 24422634 PMCID: PMC5427955 DOI: 10.1210/me.2013-1358] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Accepted: 12/12/2013] [Indexed: 12/20/2022] Open
Abstract
Retinoic acid (RA) controls many aspects of embryonic development by binding to specific receptors (retinoic acid receptors [RARs]) that regulate complex transcriptional networks. Three different RAR subtypes are present in vertebrates and play both common and specific roles in transducing RA signaling. Specific activities of each receptor subtype can be correlated with its exclusive expression pattern, whereas shared activities between different subtypes are generally assimilated to functional redundancy. However, the question remains whether some subtype-specific activity still exists in regions or organs coexpressing multiple RAR subtypes. We tackled this issue at the transcriptional level using early zebrafish embryo as a model. Using morpholino knockdown, we specifically invalidated the zebrafish endogenous RAR subtypes in an in vivo context. After building up a list of RA-responsive genes in the zebrafish gastrula through a whole-transcriptome analysis, we compared this panel of genes with those that still respond to RA in embryos lacking one or another RAR subtype. Our work reveals that RAR subtypes do not have fully redundant functions at the transcriptional level but can transduce RA signal in a subtype-specific fashion. As a result, we define RAR subtype-specific transcriptotypes that correspond to repertoires of genes activated by different RAR subtypes. Finally, we found genes of the RA pathway (cyp26a1, raraa) the regulation of which by RA is highly robust and can even resist the knockdown of all RARs. This suggests that RA-responsive genes are differentially sensitive to alterations in the RA pathway and, in particular, cyp26a1 and raraa are under a high pressure to maintain signaling integrity.
Collapse
Affiliation(s)
- Eric Samarut
- Institut de Génomique Fonctionnelle de Lyon (E.S., C.G., S.H., B.G., L.B., V.L.), Université de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique (CNRS), Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 07, France; Institut de Génétique et de Biologie Moléculaire et Cellulaire (E.S., A.A., O.L., C.R.-E.), Institut National de la Sante et de la Recherche Medicale, U596, CNRS, UMR7104, Université de Strasbourg, BP 10142, 67404 Illkirch Cedex, France.; and AltraBio SAS (S.B., P.-E.J., L.B.), Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, Vlaeminck-Guillem V. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One 2013; 8:e66278. [PMID: 23840433 PMCID: PMC3696068 DOI: 10.1371/journal.pone.0066278] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Accepted: 05/03/2013] [Indexed: 11/24/2022] Open
Abstract
Background Several data favor androgen receptor implication in prostate cancer initiation through the induction of several gene activation programs. The aim of the study is to identify potential biomarkers for early diagnosis of prostate cancer (PCa) among androgen-regulated genes (ARG) and to evaluate comparative expression of these genes in normal prostate and normal prostate-related androgen-sensitive tissues that do not (or rarely) give rise to cancer. Methods ARG were selected in non-neoplastic adult human prostatic epithelial RWPE-1 cells stably expressing an exogenous human androgen receptor, using RNA-microarrays and validation by qRT-PCR. Expression of 48 preselected genes was quantified in tissue samples (seminal vesicles, prostate transitional zones and prostate cancers, benign prostatic hypertrophy obtained from surgical specimens) using TaqMan® low-density arrays. The diagnostic performances of these potential biomarkers were compared to that of genes known to be associated with PCa (i.e. PCA3 and DLX1). Results and Discussion By crossing expression studies in 26 matched PCa and normal prostate transitional zone samples, and 35 matched seminal vesicle and PCa samples, 14 genes were identified. Similarly, 9 genes were overexpressed in 15 benign prostatic hypertrophy samples, as compared to PCa samples. Overall, we selected 8 genes of interest to evaluate their diagnostic performances in comparison with that of PCA3 and DLX1. Among them, 3 genes: CRYAB, KCNMA1 and SDPR, were overexpressed in all 3 reference non-cancerous tissues. The areas under ROC curves of these genes reached those of PCA3 (0.91) and DLX1 (0.94). Conclusions We identified ARG with reduced expression in PCa and with significant diagnostic values for discriminating between cancerous and non-cancerous prostatic tissues, similar that of PCA3. Given their expression pattern, they could be considered as potentially protective against prostate cancer. Moreover, they could be complementary to known genes overexpressed in PCa and included along with them in multiplex diagnostic tools.
Collapse
Affiliation(s)
- Dogus Murat Altintas
- Institut de Génomique Fonctionnelle de Lyon (IGFL), Université de Lyon, CNRS UMR5242, INRA1288, Ecole Normale Supérieure de Lyon, Lyon, France
| | | | | | | | | | | | | |
Collapse
|
21
|
Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, Uro-Coste E, Mokhtari K, Jouvet A, Honnorat J, Chinot O, Ramirez C, Beauchesne P, Benouaich-Amiel A, Godard J, Eimer S, Parker F, Lechapt-Zalcman E, Colin P, Loussouarn D, Faillot T, Dam-Hieu P, Elouadhani-Hamdi S, Bauchet L, Langlois O, Le Guerinel C, Fontaine D, Vauleon E, Menei P, Fotso MJM, Desenclos C, Verrelle P, Ghiringhelli F, Noel G, Labrousse F, Carpentier A, Dhermain F, Delattre JY, Figarella-Branger D. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One 2012; 7:e45950. [PMID: 23071531 PMCID: PMC3468603 DOI: 10.1371/journal.pone.0045950] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Accepted: 08/23/2012] [Indexed: 12/16/2022] Open
Abstract
Anaplastic oligodendrogliomas (AOD) are rare glial tumors in adults with relative homogeneous clinical, radiological and histological features at the time of diagnosis but dramatically various clinical courses. Studies have identified several molecular abnormalities with clinical or biological relevance to AOD (e.g. t(1;19)(q10;p10), IDH1, IDH2, CIC and FUBP1 mutations). To better characterize the clinical and biological behavior of this tumor type, the creation of a national multicentric network, named “Prise en charge des OLigodendrogliomes Anaplasiques (POLA),” has been supported by the Institut National du Cancer (InCA). Newly diagnosed and centrally validated AOD patients and their related biological material (tumor and blood samples) were prospectively included in the POLA clinical database and tissue bank, respectively. At the molecular level, we have conducted a high-resolution single nucleotide polymorphism array analysis, which included 83 patients. Despite a careful central pathological review, AOD have been found to exhibit heterogeneous genomic features. A total of 82% of the tumors exhibited a 1p/19q-co-deletion, while 18% harbor a distinct chromosome pattern. Novel focal abnormalities, including homozygously deleted, amplified and disrupted regions, have been identified. Recurring copy neutral losses of heterozygosity (CNLOH) inducing the modulation of gene expression have also been discovered. CNLOH in the CDKN2A locus was associated with protein silencing in 1/3 of the cases. In addition, FUBP1 homozygous deletion was detected in one case suggesting a putative tumor suppressor role of FUBP1 in AOD. Our study showed that the genomic and pathological analyses of AOD are synergistic in detecting relevant clinical and biological subgroups of AOD.
Collapse
Affiliation(s)
- Ahmed Idbaih
- Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
The present study was conducted to estimate the association of the scores on the subscales of the Defense Mechanisms Inventory to the Denial Score on the COPE for 91 volunteers who were undergraduates and 7 graduate students. There were 31 men and 67 women; 77 were white and 21 were nonwhite. Both inventories were administered in a group format. The intercorrelations of COPE—Denial and subscales of the Defense Mechanisms Inventory did not approach significance; this supports the Haan/Kroeber hypothesis suggesting that a qualitative difference be made between coping and defensiveness and the Lazarus/French hypothesis suggesting a dichotomy of “problem-focused” coping and “emotion-focused” coping.
Collapse
|